Publications by authors named "Rene-Marc Flipo"
Objectives: To evaluate the effectiveness of short message service (SMS) and/or email reminders in improving influenza vaccination coverage rates among rheumatoid arthritis (RA) patients treated with anti-TNF therapies, and to identify factors associated with vaccination.
Methods: A nested randomized controlled trial in the ART e-cohort, an ongoing French nationwide multicentre prospective cohort of RA patients treated with anti-TNF therapy. Patients were 1:1 randomized, with stratification on age.
Article Synopsis
- A study compared two methods for stopping glucocorticoids in rheumatoid arthritis patients with low disease activity: replacing prednisone with hydrocortisone or tapering prednisone down gradually.
- The trial included 102 patients and found that after 12 months, 55% in the hydrocortisone group and 47% in the tapering group successfully discontinued glucocorticoids, showing no significant difference between the groups.
- The results indicated that neither strategy was superior for achieving discontinuation, and there were no serious side effects related to adrenal insufficiency observed.
Article Synopsis
- The study aimed to compare the antibody response to SARS-CoV-2 in patients with inflammatory rheumatic diseases and healthy individuals.
- Researchers screened unvaccinated patients with conditions like rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis in France, and matched them with seropositive healthcare workers as controls.
- Results showed no significant difference in antibody levels between both groups, with a trend indicating that patients with severe COVID-19 symptoms had higher antibody titres; treatments like glucocorticoids seemed linked to lower antibody responses.
Article Synopsis
- The study evaluated the retention rates, safety, and predictive factors for the use of subcutaneous TNF inhibitors (TNFi) in patients with axial spondyloarthritis (axSpA) based on real-life data from 552 patients.
- Results indicated that golimumab (GOL) had a significantly higher retention rate compared to adalimumab (ADA), etanercept (ETN), and certolizumab pegol (CZP), especially when prescribed as the first treatment option.
- Predictive factors for treatment cessation included female sex, peripheral disease, and the line of treatment, with primary inefficiency being the most common reason for stopping treatment.
Objective: The EULAR task force recently published the difficult-to-treat RA (D2T RA) definition, however, a definition of D2T axSpA is still lacking and limitations in this definition exist. The objectives were to study the characteristics of D2T axSpA patients using the EULAR definition and to study a subgroup of patients with a predefined more stringent definition including a temporal criterion.
Methods: A multicentric retrospective study was performed.
Article Synopsis
- Septic bursitis (SB) is a prevalent inflammatory condition, particularly linked to certain professions, and currently lacks standardized management guidelines.
- A collaborative group of healthcare specialists developed specific recommendations for treating olecranon and prepatellar SB, using a combination of literature review and expert insights.
- The newly established guidelines, aimed at various healthcare providers, emphasize the role of biological tests, imaging, antibiotic treatments, and address surgical options and prevention strategies.
Real-world effectiveness of golimumab in the treatment of patients with active rheumatoid arthritis, psoriatic arthritis, or axial spondyloarthritis who failed initial TNF-α inhibitor therapy: a pooled analysis of European prospective observational studie.
Clin Exp Rheumatol
March 2024
Objectives: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) patients often experience secondary non-response to a first-line tumour necrosis factor alpha inhibitor (TNFαi). This pooled analysis of six observational studies in Europe (GO-BEYOND program) provides an estimate of second-line golimumab (GLM) effectiveness for these rheumatic diseases.
Methods: The GO-BEYOND studies included common disease-specific endpoints allowing for a pooled analysis.
Objective: The EULAR task force recently published the difficult-to-treat rheumatoid arthritis (D2T RA) criteria, however, a definition of D2T patients in psoriatic arthritis (PsA) is still lacking. To date, we have little data concerning D2T PsA, especially in real-world. One of the limitations of the D2T RA EULAR definition is the absence of a temporal criterion.
View Article and Find Full Text PDFObjectives: To investigate whether the efficacy and safety data from drug-registration trials can be extrapolated to real-life RA patients receiving RTX.
Methods: The 'AutoImmunity and Rituximab' (AIR-PR) registry is a French multicentre, prospective cohort of RA patients treated with RTX in a real-life setting. We compared treatment responses at 12 months and serious adverse events (AEs) between eligible and non-eligible patients, by retrieving the eligibility criteria of the three rituximab-registration trials.
Objectives: The efficacy of anti-IL-6 receptors such as tocilizumab (TCZ) was demonstrated in patients with PMR in two recent randomized controlled trials. The objective of this multicentre retrospective study was to assess the efficacy of TCZ in PMR patients requiring glucocorticoid (GC)-sparing treatment, as well as different strategies for TCZ withdrawal.
Methods: We conducted a multicentre study in French tertiary healthcare departments for patients with PMR.
Objectives: The objective of the current study was to evaluate the severity of COVID-19 and identify factors associated with severe disease outcomes in patients with spondyloarthritis (SpA), a chronic inflammatory rheumatic and musculoskeletal disease (RMD).
Methods: We utilized patient data from the French national multicenter RMD COVID-19 cohort (NCT04353609). The primary outcome was to describe COVID-19 characteristics in patients with SpA based on disease severity of COVID-19 (mild, moderate or severe) with serious infection including moderate and severe cases.
Introduction: We aimed to evaluate the utility of FDG-PET/CT in diagnosing polymyalgia rheumatica (PMR) and associated large-vessel vasculitis (LVV).
Methods: We analyzed FDG-PET/CT completed between 2015 and 2019 on patients diagnosed with PMR. For comparisons, patients with PMR were matched 1:1 to controls based on age and gender.
Introduction: Autoimmune/inflammatory rheumatic diseases (AIRDs) patients might be at-risk of severe COVID-19. However, whether this is linked to the disease or to its treatment is difficult to determine. This study aimed to identify factors associated with occurrence of severe COVID-19 in AIRD patients and to evaluate whether having an AIRD was associated with increased risk of severe COVID-19 or death.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the characteristics of rheumatoid arthritis patients starting Janus Kinase Inhibitors (BARI and TOFA) before and after the VTE risk warnings issued by the European Medicine Agency (EMA).
- It found no significant differences in baseline VTE risk factors for patients initiating these medications before versus after the warnings, although there was a trend towards fewer patients with a history of VTE afterward.
- The persistence rate for using BARI and TOFA over two years was similar, indicating that both medications remained equally effective in the long-term treatment of RA despite VTE concerns.
Background: Disc-related sciatica is a frequent condition. Most cases of sciatica evolve favorably. Although several randomized controlled trials have reported that surgery is more effective than conservative management in the short-term, no significant differences in pain or functional disability have been reported in the longer term.
View Article and Find Full Text PDFMusculoskeletal corticosteroid injections are widely performed, although the exact practice varies greatly due to advances in knowledge and techniques. This justifies updating and drawing up good practice recommendations. Using a consensus model formalized by the French National Authority for Health (HAS) and based on a literature review that resulted in a "white book", 13 recommendations were developed by a group of experts.
View Article and Find Full Text PDFSelf-reported Impact of the Early 2020 COVID-19 Crisis on the Healthcare Pathway During and After Lockdown in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Practical Survey.
J Patient Exp
December 2022
Article Synopsis
- - The study investigated the effects of the COVID-19 lockdown on patients with chronic immune-mediated inflammatory diseases (IMIDs) through a survey conducted among 4,500 patients in various medical departments from March 17 to July 11, 2020.
- - Out of the surveyed patients, about 20% responded to the first survey during the lockdown, revealing that nearly 46% experienced disrupted follow-up care, a trend mirrored in a subsequent survey conducted two months post-lockdown.
- - The findings highlighted that patients across all departments had similar negative perceptions regarding their healthcare follow-ups during and after lockdown, emphasizing the need for a collaborative approach in managing chronic conditions during crises.
Article Synopsis
- Anterior atlanto-axial subluxation (AAS) is a condition that can develop in rheumatoid arthritis (RA) patients and can lead to severe neurological problems; this study aimed to find the prevalence and predictors of AAS after 12 years in early polyarthritis patients.
- The research followed 323 patients enrolled in the ESPOIR cohort, finding that only 4.6% had AAS, with specific factors like IgA RFs at baseline and CRP/RFs after 10 years being associated with the condition.
- Despite some associations found, the rarity of severe AAS cases suggests that these findings may not have significant clinical importance for predicting the condition's occurrence.
Article Synopsis
- - Dealing with patients who have both multiple sclerosis (MS) and inflammatory rheumatic disorders (IRDs) is common for rheumatologists, due to the statistical connection between conditions like spondyloarthritis (SpA) and MS.
- - Although TNF inhibitors (TNFi) have been seen as a contraindication for patients with pre-existing demyelinating diseases based on past research, new epidemiological studies suggest that TNFi may not actually trigger MS.
- - The review highlights the relationship between MS and IRDs, discusses the effects of disease-modifying anti-rheumatic drugs (DMARDs) on MS, particularly focusing on TNFi, and notes the lack of clear guidelines for treating patients with both conditions.